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Behc ¸et’s disease (BD) is a systemic inﬂammatory disorder characterized mainly by recurrent oral and genital ulcers and
eye involvement. Although the pathogenesis remains poorly understood, a variety of studies have demonstrated that genetic
predisposition is a major factor in disease susceptibility. Peculiar geographical distribution of BD along the ancient Silk Road
has been regarded as evidence supporting genetic inﬂuence. The observed aggregation of BD in families of patients with BD is also
supportive for a genetic component in its etiology. HLA-B51 (B510101 subtype) is the most strongly associated genetic marker for
BD in countries on the Silk Road. In recent years, several genome-wide association studies and genetic polymorphism studies have
also found new genetic associations with BD, which may have a supplementary role in disease susceptibility and/or severity. The
author reviewed the HLA and non-HLA genetic association studies.
1.Introduction
Behc ¸et’s disease (BD) is a complex syndrome characterized
mainly by recurrent oral aphthous ulcers, genital ulcerations,
and ocular involvement. This triple-symptom complex was
ﬁrst described by Hulusi Behc ¸et, a Turkish dermatologist, as
a separate disease entity. Later, other associated clinical fea-
tures were described [1, 2]. Although the aetiology is still
obscure, BD is believed to be triggered by environmental
factorssuchasmicrobialagentsinindividualswithaparticu-
lar genetic background. Interactions of genetic and environ-
mental factors in BD patients may underlie pathogenic pro-
cesses, which may inﬂuence the development of the disease
andmodifyitscourse.Theprevalentdistributioninaspeciﬁc
geographical area, the close association with HLA-B51 in
diﬀerent ethnic groups, and the familial clustering of BD are
hallmarksaccountingforthestrongcontributionofagenetic
background [2, 3]. Here we review the current knowledge of
thegeneticbasisofBDandtheirimplicationsinpathogenesis
of BD and summarize the important ﬁndingsin Table 1.
2. GeographicalDistribution
The prevalence of BD is known to be high in Japan,
China, Turkey, and the Mediterranean and the Middle
Eastern countries. It is hypothesized that this geographical
distribution of BD from Japan to the Middle East and
the Mediterranean basin correlates with the distribution
of HLA-B51 by old nomadic or Turkish tribes via the
ancient Silk Road. This peculiar geographical distribution
have been regarded as evidence supporting genetic inﬂuence
on the pathogenesis of BD [1, 4, 5]. The highest prevalence
rates of BD were reported from Turkey as 420/100.000 in
Istanbul, 380/100.000 in a rural area in northern Turkey,
and 110/100.000 in Ankara [6–8]. Usually prevalence rates
between %7/100.000 and %30/100.000 were reported in
Middle East, Mediterranean, and Far East countries [1, 9].
It is rarely seen in Western and Northern Europe and United
States, for example, its prevalence reported 2,26/100.000 in
Germany and 5,2/100.000 in the United States [10, 11]. In
sub-Saharan Africa, Australasia, and among Amerindians
the disease is rare or almost absent [9]. The prevalence
of BD in Berlin was reported to be the highest among
Lebanese(101.3/100000)andTurkish(77.3/100000)people,
while the lowest prevalence was reported among Germans
(1.4/100000)[12].TheseﬁndingssuggestthatBDprevalence
is mostly dependent on ethnic origin and genetic factors
rather than environmental factors [9, 12].
3.HLA-B51andOther HLAGenesAssociated
withBD
HLA-B51, one of the split antigens of HLA-B5, has been
found to be the most accurate genetic marker for BD to date2 Pathology Research International
Table 1: Findings supporting the genetic background of Behc ¸et’s disease.
Studies Findings/associations
Epidemiology Geographical distribution: from Japan to the Middle East and the Mediterranean basin
Ethnic origin Prevalence in Berlin: high in Lebanese and Turks and low in Germans
HLA HLA-B51 (B510101 subtype)
Genome-wide association studies
(i) MHC Class I region: HLA-B51 (B5101)
(ii) Non-HLA regions: IL10 region and region between IL23R and IL12RB2
(iii) Chromosome regions: 6q25-26, 12p12–13
Familial aggregation (i) In patients with pediatric onset
(ii) Autosomal-recessive Mendelian mode of inheritance in a pediatric subgroup
Twin concordance studies High concordances in monozygotic twins
Gene polymorphism studies Inconsistent and weak associations, further investigations are needed for deﬁnitive
conclusions
in diﬀerent ethnic groups. However, its contribution to the
overall genetic BD susceptibility was estimated about to be
20% [13]. The HLA-B51 is frequent in BD patients, with
a range of 40–80% in ethnic groups including Turkish,
European, and Asian populations from the Middle East to
the Far East, whereas it can be as low as 13% among white
patients in western countries [3, 9]. And in our study, we
observed HLA-B51 in 46 (54.1%) of our 85 Turkish patients
[1]. In general, the strongest correlation between BD and
HLA-B51 is seen among populations with a high incidence
of HLA-B51 and BD, and the weakest correlation is seen in
populations where BD and HLA-B51 are rare [1, 9]. In a
recent meta-analysis of 4,800 patients with BD and 16,289
controls from 78 independent studies, the pooled odds ratio
(OR) of HLA-B51/B5 allele carriers to develop BD compared
with noncarriers was found to be 5.78 (95% CI 5.00–6.67).
They found that the pooled rates of HLA-B51/B5-positive
BDcasesvariedacrossgeographiclocations,butinterestingly
the relative risk increases associated with this allele appeared
to be fairly even for diﬀerent ethnic populations [14].
There are more than 89 diﬀerent subtypes of HLA-B51,
and HLA-B5101 is the major suballele associated with BD
in all the populations studied. HLA-B5108 was also found
to be associated with BD in the Middle Eastern, Italian,
Spanish, Greek, Turkish, and German patients. Oppositely,
it has been suggested that HLA-B5107 might be negatively
associated with BD in the Turkish and German populations
[3, 9]. Recently, Y. Takemoto et al. investigated HLA-B5101
gene from Japanese, Turkish, Jordanian, and Iranian patients
and found that all the patients have B510101 suggesting
that the susceptibility to BD was conferred by the B510101
subtype and not by any genes in linkage disequilibrium
with HLA-B51 [15]. Accordingly, Amerindian populations,
known to carry a high frequency of HLA-B51 but having no
BD incidence, are known to carry the highest frequencies of
nonsusceptible HLA-B510201 allele [9, 16].
In our study, we also investigated the association of
HLA class I alleles with the manifestations of BD. We found
that BD patients with HLA-B51 antigen are almost four
times more likely to have thrombophlebitis than patients
without it. We also found some less signiﬁcant associations:
decreased HLA-B35 frequency in patients with throm-
bophlebitis, increased HLA-A29 and decreased HLABw6
frequency in patients with ocular involvement, decreased
HLA-Cw2 frequency in patients with erythema nodosum,
and decreased HLA-Cw7 frequency in patients with genital
ulceration [1]. Zouboulis et al. also found that both superﬁ-
cialthrombophlebitisanddeepthrombosissigniﬁcantlywere
more frequent in HLA-B5-positive BD patients compared
with HLA-B5-negative patients. They did not observe any
other association between the class I HLA antigens and
manifestations of BD [17]. Alekberova et al. found super-
ﬁcial thrombophlebitis statistically more frequent in HLA-
B5-positive BD patients [18]. However, Muftuoglu et al.
observed no HLA allele association with thrombophlebitis,
ocular involvement, arthritis, and erythema nodosum in BD
patients [19].
The pathogenetic role of HLA-B51 in BD has yet to
be elucidated. However, HLA-B51 molecule itself may be
responsible, at least in part, for neutrophil hyperfunction in
BD, since HLA-B51-transgenic mice show enhanced neutro-
phil function as seen in BD patients, although these mice
did not develop the symptoms of BD [20]. Because a pri-
mary role of HLA class I antigens such as HLA-B51 is to
present endogenous peptides to CD8+ T cells, the lack of the
disease phenotype in this mouse model can be explained by
the absence of an triggering microbial or injury-related pep-
tide that would activate the disease-relevant CD8+ T cells.
MICA (9-mer peptide AAAAAIFVI) is a stress-inducible an-
tigenic peptide, and it is one of the many triggering can-
didates of BD. Yasuoka et al. showed that only HLA-B51-
positive BD patients with active disease showed a MICA-
mediated cytotoxicity and they also showed that this speciﬁc
T cell response was lost after the BD-related symptoms dis-
appeared [21]. Superoxide production by neutrophils was
also reported to be increased in HLA-B51-positive individ-
uals [22]. These ﬁndings suggest that HLA-B51 could be
associated with neutrophil hyperfunction in BD.
S e v e r a lo t h e rH L Ac l a s sIa n dc l a s sI Ia l l e l e si n c l u d -
ing HLA-A26, HLA-B15, HLA-B5701, HLA-B2702, HLA-
B3901,HLA-B52,HLA-B56,Cw1,Cw14,Cw15,Cw16,HLA-
DRB104, and HLA-DRB107 have been described to bePathology Research International 3
associated with BD in diﬀerent populations. Positive and
negative associations with nonclassical HLA-E, HLA-F, and
HLA-G polymorphisms were also detected in Korean and
Japanese patients. But because of their low incidence or the
small size of investigated populations, mostly signiﬁcance
levels have been weak and most of them were achieved in
single studies only. Therefore, they are generally not consid-
ered to give primary susceptibility to the disease. In addition,
since there is strong linkage disequilibrium within the MHC
region it is not clear whether these associations cause sus-
ceptibility to BD or they have a linkage disequilibrium with
HLA-B51. Among these associations HLA-A26, HLA-B15,
and HLA-B5701 were found to be independently associated
with BD [1, 3, 9, 23–25].
The MHC class I chain-related gene A (MIC-A) was also
regarded as a candidate for BD genetic susceptibility. Sev-
eral studies have demonstrated associations between MIC-
A009, MIC-A006, MIC-A6 TM, and BD. However, these
associations appear to be the result of a strong linkage dise-
quilibrium of MIC-A with HLA-B51, so today they are not
considered as the primary susceptibility genes for BD [9, 26].
4. Genome-WideAssociationStudies (GWASs)
GWAS can facilitate new unbiased biologic insights into
disease pathogenesis, and they can provide more deﬁnite
answers for the cause of the diseases of complex genetic
trait when performed in large groups and conﬁrmed in
diﬀerent populations. The ﬁrst GWAS was relatively small
and was reported in Turkish BD patients: Fei et al. identiﬁed
genetic associations between BD and single-nucleotide poly-
morphisms (SNPs) in KIAA1529, CPVL, LOC100129342,
UBASH3B, and UBAC2 (OR = 2.04, 2.26, 1.84, 1.71, and
1.61, resp.). Interestingly, none of these ﬁve susceptibility
loci had been associated with BD before. The functions of
two are not known, and the genes UBASH3B and UBAC2
both contain a UBA, suggesting that both gene products are
involved in the ubiquitination pathway. CPVL gene encodes
for a carboxypeptidase that cleaves a single amino acid from
the carboxy terminus of proteins or peptides [27].
Remmers et al. performed a GWAS with 311,459 SNPs
in 1215 BD patients and 1278 healthy controls from Turkey.
They conﬁrmed HLA-B51 association and identiﬁed a sec-
ond,independentassociationwithintheMHCClassIregion.
In addition, the results of the meta-analysis including a
total of 2430 cases and 2660 controls established associations
with the interleukin10 (IL10) variant (OR: 1.45) and with
a variant located between the IL23 receptor (IL23R) and
IL12 receptor β2 (IL12RB2) genes (OR: 1.28) [28]. Recently,
Mizuki et al. performed a similar GWAS using a larger
sample pool using 500, 568 SNPs in 612 Japanese individuals
with BD and 740 unaﬀected controls, and the HLA-B region
showed the most signiﬁcant association with BD (rs4959053,
P = 1.8×10
−26).Theyalsodetectedgenome-widesigniﬁcant
associations outside the HLA complex, at P = 2.7 × 10
−8 for
rs12119179, which is located in the 47kb intergenic region
between IL23R and IL12RB2. The second strongest region
of association they found was rs1554286, located within
the intron 3 of IL10 (P = 8.0 × 10
−8)[ 29]. The results of
these 2 large GWASs provide cross-validation of these two
non-HLA regions, IL10 and IL23R-IL12RB2 associations
in two distinct populations. IL23 is a heterodimeric pro-
inﬂammatory cytokine that has been shown to stimulate
T helper cell proliferation and increase the production of
inﬂammatory cytokines such as IL1, IL6, IL17, and TNFα.
IL10 is a potent suppressor of inﬂammatory cytokines such
as IL1, IL6, IL12, TNFα and IFNγ and inhibits T cell and NK
cell activation [29].
Meguro et al. also performed a GWAS in BD among
23.465 microsatellites, and 6 best positively associated
microsatellites (of a total of 147) (D3S0186i, D6S0014i,
D6S0032i, 536G12A, D12S0645i, and D22S0104i) with BD
were identiﬁed. New studies are needed to identify the im-
portance of these microsatellites in the pathogenesis of BD.
They also performed a class I HLA analysis. They found
HLA-B5101 as the strongest susceptibility allele for the de-
velopment of BD. Interestingly, among the HLA-B5101-neg-
ative patients, HLA-A26 was found to be the most strongly
associated allele with BD (allele: 25.9% versus 10.6%, OR =
2.96). Signiﬁcantly increased incidences of HLA-F010101
and HLAG010102 in patients with BD probably result from
linkage disequilibrium with HLA-A26 [30]. In previous
studies, HLA-A26 was signiﬁcantly associated with BD in
Japanese, Taiwanese, and Greek populations. On the con-
trary, in Ireland, Italy, and Turkey, HLA-A26 was increased
in healthy controls compared with patients with BD, but
not signiﬁcantly [30]. Karasneh et al. performed a whole-
genome linkage analysis with 395 microsatellite markers and
identiﬁed 16 potential loci for BD, 1p36, 4p15, 5q12, 5q23,
6p22–24, 6q16, 6q25-26, 7p21, 10q24, 12p12-13, 12q13,
16q12, 16q21–23, 17p13, 20q12-13, and Xq26–28 with the
strongest evidence seen for 12p12-13 and 6p22–24 [31]. Two
chromosome regions were consistent with the regions of two
BD susceptibility markers, 536G12A and D12S0645i, which
were located on 6q25.1 and 12p12.1, which were found by
Meguro et al. in their genome-wide association study [30].
5. FamilialAggregation
Familial aggregation has been also regarded as an evidence
supporting the genetic predisposition to BD and has been
reported in 1–18% of the patients, mostly of Turkish, Israeli
and Korean origin, and it is increased in patients with
juvenile disease and is especially manifest in families of
probands carrying HLA B51. The familial aggregation of BD
has been observed in diﬀerent ethnic groups with a variable
frequency. It is higher in Turks (18.2%), Koreans (15.4%),
and Jews (13.2%) than in Chinese (2.6%), Japanese (2.2%),
and Europeans (1%) [3, 32–34].
Analysis of a small group of multicase families did not
demonstrate any particular Mendelian inheritance pattern
[35]. However, a recent study provided evidence of an autos-
omal-recessive Mendelian mode of inheritance in a pediatric
BD subgroup suggesting that genetic load might be higher in
children with BD than in adults [36]. A genetic anticipation,
in the form of earlier disease onset in the children of the
aﬀectedparents,hasalsobeenobservedinagroupofTurkish4 Pathology Research International
families. The expansion of unstable trinucleotide repeats has
been proposed as the genetic basis of the defect in familial
cases[37].Treudleretal.observedthatjuvenile-onsetdisease
wascharacterizedbyanincreaseinfamilialcases(25%versus
8% in patients with adult onset; P = .047) [38]. Laghmari
et al. evaluated clinical characteristics of BD in Moroccan
children, and they reported the familial disease in 30.7%
of their cases, which is the highest familial aggregation rate
reported so far [39]. I. Kon´ e-Paut reported that 13 of the
106 pediatric patients (12.3%) and 9 of the 399 nonpediatric
patients (2.2%) had relatives aﬀected by BD. This excess
of familial cases in the pediatric group compared with the
nonpediatric group was found to be signiﬁcant (P<. 0001).
They also found that the mean age of attaining criteria in
familial cases (17. 95 years) was signiﬁcantly lower than in
sporadic cases (27.28 years; P<. 0001), and they proposed
the inclusion of familial history in the deﬁnition of pediatric
BD [40].
Akpolat et al. evaluated 27 patients with familial BD in
12 families. Among the 137 patients they studied, the rate
of familial form of BD was 8.7%. Vascular involvement
was 7.4% (2/27) in the familial group, while it was 28.8%
(36/125) in patients without the familial form of the disease
(P<0.01). They also observed a high rate of (68%) HLA-
B51 positivity in the familial form [33]. Recurrence most
commonly occurs between siblings, but also there are moth-
er/son, mother/daughter, father/son, father/daughter, cous-
in/cousinanduncle/nephewcases[3].Thesiblingrecurrence
risk of BD was reported to be 4.2% in Turkey, and the
recurrence risk ratio (λs) was estimated to be 11.4–52.5
in Turkish populations [41]. In familial BD, the HLA-B51
positivity is much more frequent than in sporadic cases,
being 68-83.3% in Turkish studies. The HLA-B51 homozy-
gosity is common in familial cases [33, 42].
Twin concordance studies are frequently being used for
estimating the role of genetic factors in the pathogenesis of
multifactorial diseases. In a recent twin study of Masatlioglu
et al., the pairwise concordance rate for BD was 2/6 for mo-
nozygotic twins and 1/8 for dizygotic twins. In this study
genetic eﬀects accounted for 41% of the phenotypic variance
for BD among twins. The higher concordances for BD in
monozygotic twins compared with dizygotic twins suggests
geneticpredisposition[43].Inaddition,therearetworeports
of monozygotic twins concordant for BD [43, 44]. In one
of these twins reports both patients interestingly showed
intestinal BD; however, they were HLA-B51 negative [44].
In the other report, the twin brothers were both HLA-B51
positiveanddevelopedthediseaseatthesameage[45].There
isalsoonereportofapairofHLA-B51-negativemonozygotic
twins discordant for BD in the literature [46].
6. Immunogenetics and Gene
Polymorphism Studies
Cytokine-mediated immunity plays a crucial role in the
pathogenesis of various immunologically mediated diseases.
It has been suggested that polymorphisms of genes involved
inimmunopathogenesisofdiseasescombiningwithenviron-
mentalfactorsmaybeimportantinthedevelopmentofthese
diseases. Several genes such as IL genes (IL-1A, IL-1B, IL-
1 receptor antagonist, IL-2, IL-6, IL-10, IL-12B promoter, IL-
17F, IL-18, IL-23R genes), tumor necrosis factor (TNF) genes,
transporter associated with antigen processing (TAP) gene,
intercellular adhesion molecule-1 (ICAM-1) gene, endothelial
nitric oxide synthase (eNOS) gene, glutathione S-transferase
gene, N-acetyltransferase gene, and vascular endothelial
growth factor (VEGF) gene polymorphisms have been related
to BD susceptibility. However, in these studies signiﬁcance
levels were mostly weak, most of them were achieved in
single studies and if there are multiple studies the results are
mostly conﬂicting. For example, eNOS gene polymorphism
was reported to be associated with BD susceptibility in
Italian and Korean, but not in Turkish and Japanese patients.
Therefore their role in BD pathogenesis is not clear, and
further investigations are needed for deﬁnitive conclusions
[3, 47–52].
Thrombosis is a common complication of BD and the
pathogenic mechanism of thrombotic tendency in BD is
not well known. The role of procoagulant polymorphisms
and mutations has also been investigated in BD. As platelet
membrane glycoprotein gene polymorphisms have been iden-
tiﬁed as risk factors for thrombosis we investigated the
association of the platelet glycoprotein Ia C807T/G873A gene
polymorphism and thrombosis in BD and we found that
the risk of thrombosis is signiﬁcantly higher in patients who
have 807TT and 807CT genotypes than in patients who have
807CC genotype [53]. Associations of factor V Leiden and
prothrombin g e n em u t a t i o n sw i t hB Dw e r ec o n ﬁ r m e di n
some studies, but not in others [3, 54, 55]. We also inves-
tigated the association between the factor V Leiden and pro-
thrombin gene mutations with BD and we found a signiﬁ-
cantly high prevalence of the prothrombin gene mutation in
patients with BD patients than in control subjects [56].
Herewereviewthecurrentknowledgeofthegeneticbasis
of BD. However, it has been evident that there are similarities
anddiﬀerencesinBDsusceptibilitylociacrossethnicgroups.
Therefore,eﬀortstoidentifyethnic-speciﬁcgeneticfactorsor
disease-causing variants are needed for the genetic dissection
of BD.
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